Neither TA-1 or LL-37 has been approved by the U.S. Food and Drug Administration. They can only be prescribed through licensed clinicians where state law allows.

Yes, TA-1 has been extensively studied in humans for immune regulation and infection recovery, including in viral and cancer-related settings. LL-37 has early human and animal research suggesting roles in immune defense, wound healing, and antimicrobial protection.

Together, TA-1 + LL-37 are designed to support immune balance, reduce inflammation, and enhance tissue repair. Thymosin Alpha-1 helps modulate immune response and T-cell activity, while LL-37 acts as a broad-spectrum antimicrobial peptide that may aid healing and barrier protection.

In clinical research, TA-1 is well tolerated, with few reported side effects. LL-37 has shown a good safety profile in early studies when professionally compounded and properly dosed. The most common issue is mild redness or irritation at the injection site.

Anyone who is pregnant, nursing, immunocompromised, or managing autoimmune conditions should only use this therapy under direct medical supervision. Individuals with active infections or chronic inflammatory disease should disclose all medications to their provider.

TA-1 + LL-37 are usually given as subcutaneous injections, once or several times per week, based on immune or recovery goals.

This peptide pairing is often used in immune, anti-inflammatory, or regenerative protocols, and may complement peptides like BPC-157 for recovery or MOTS-C for metabolic support. Any stack should be clinician-supervised.